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Abstract We performed a multi-centre randomized con-
trolled trial to compare the efficacy of mycophenolate
mofetil (MMF) to that of cyclosporine A (CsA) in treating
children with frequently relapsing nephrotic syndrome and
biopsy-proven minimal change disease. Of the 31 random-
ized initially selected patients, seven were excluded. The
remaining 24 children received either MMF 1200 mg/m2
per day (n=12) or CsA 4–5 mg/kg per day (n=12) during a
12-month period. Of the 12 patients in the MMF group, two
discontinued the study medication. Evaluation of the
changes from the baseline glomerular filtration rate showed
an overall significant difference in favour of MMF over the
treatment period (p=0.03). Seven of the 12 patients in the
MMF group and 11 of the 12 patients in the CsA group
remained in complete remission during the entire study
period. Relapse rate in the MMF group was 0.83/year
compared to 0.08/year in the CsA group (p=0.08). None of
the patients reported diarrhea. Pharmacokinetic profiles of
mycophenolic acid were performed in seven patients. The
patient with the lowest area under the curve had three
relapses within 6 months. In children with frequently
relapsing minimal change nephrotic syndrome, MMF has
a favourable side effect profile compared to CsA; however,
there is a tendency towards a higher relapse risk in patients
treated with MMF.
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Introduction
Nephrotic syndrome in children is primarily (77%) caused
by minimal change disease [1]. The vast majority (92%) of
these patients will respond well to corticosteroids. However,
as many as 70% of children with nephrotic syndrome
experience at least one relapse, and 30% will develop a
more complicated course with frequent relapses (≥2 relapses/
6 months) with or without steroid dependency (relapse
during tapering or within 2 weeks after discontinuation of
corticosteroids) [2, 3]. A short course of cyclophosphamide
(2–3 months 2–3 mg/kg per day) will lead to prolonged
remission in 25–60% of children with frequently relapsing
nephrotic syndrome [4, 5]. Most patients (80%) who do not
respond to cyclophosphamide can achieve prolonged
remission with cyclosporine A (CsA), but long-term
treatment can have harmful side-effects of which nephro-
toxicity and hypertension are the most critical [6–11].
The results from several uncontrolled studies have
recently suggested a positive effect of the relatively new
immunosuppressive drug mycophenolate mofetil (MMF) in
preventing relapses in children with frequently relapsing
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nephrotic syndrome due to minimal changes and various
other nephropathies [12–21]. Mycophenolate mofetil inhibits
inosine monophosphate dehydrogenase, an enzyme required
for the de novo pathway of purine synthesis which, in turn, is
essential for the proliferation of B and T lymphocytes. In
contrast with CsA, MMF has no known nephrotoxic side
effects. To the best of our knowledge, there are currently no
randomized controlled studies comparing the efficacy of
MMF and CsA in treating nephrotic syndrome in children or
adults. Furthermore, pharmacokinetic profiles of MMF in
children are scarce and mainly concern renal transplant
recipients using multiple drugs [22, 23].
We performed a randomized controlled trial to study the
efficacy and side effects of MMF compared to CsA in
children with frequently relapsing nephrotic syndrome and
biopsy proven minimal change disease.
Methods
General outline of the study
This was a multi-centre randomized controlled trial aimed
at studying the efficacy and side effects of MMF compared
to CsA in children with frequently relapsing nephrotic
syndrome. We also performed a pharmacokinetic study of
MMF. Patients were enrolled between January 2003 and
June 2005 in six University Hospitals in the Netherlands
and Belgium. The ethics committees of the hospitals
approved the study protocol. Informed consent was
obtained after written and oral information was given.
Inclusion and exclusion criteria
Children (<18 years) with frequently relapsing nephrotic
syndrome with or without steroid dependency, despite
cyclophosphamide therapy, were asked to participate in
the study. Inclusion requirements were glomerular filtration
rate (GFR) >80 ml/min per 1.73 m2 and biopsy-proven
minimal change disease. Patients already on CsA medication
were still eligible for the study. The children had to be in
remission at study entry (trace or nil proteinuria, as
determined by the dipstick test or <100 mg/dl for at least
3 days). Patients with severe leucopenia (leucocytes <3.0×
1000 cells/mm3), severe anemia (haemoglobin <8.9 g/dl) or
active infection were excluded from the study.
Study medication
Group A patients were treated for 12 months with MMF,
1200 mg/m2 per day b.i.d. (two doses per day, maximum
dose 1 g twice daily). In the case of severe leucopenia, severe
anemia, diarrhea (see Follow-up) or serious infection, the
dose was decreased by 25%. If side effects persisted, the dose
was reduced by an additional 25% of the initial dose. Dose
adjustment was not based on mycophenolate trough levels.
Group B patients were treated for 12 months with the
conventional treatment, which consists of CsA 4–5 mg/kg per
day b.i.d. The dose was adjusted aiming at trough levels of
50–150 µg/l. In total, four different assays were used [six
patients, EMIT (enzyme multiplied immunoassay technique);
three, FPIA (fluorescence polarization immunoassay); two,
ACMIA (antibody conjugated magnetic immunoassay ); one,
AxSYM (human chorionic gonadotropin test)]; however, all
participating centres standardly aim at a trough level of 50–
150 µg/l for their nephrotic patients irrespective of the method
used. In patients already on CsA medication at study entry,
the CsAwas tapered and stopped within 2 weeks after starting
MMF therapy (group A) or continued (group B).
Nephrotic syndrome relapses, defined as proteinuria of 3+
or more by the dipstick test or >40 mg/m2 per hour for more
than 3 days after a period of remission, were treated with
prednisolone 60 mg/m2 once daily until remission was
achieved, followed by 4 weeks of 40 mg/m2 every other
day or other tapering regimes at the discretion of the treating
pediatrician.
Follow-up
Every 3 months during the study-period of 12 months, the
number of relapses, (gastro-intestinal) side effects and
additional medication were noted. Diarrhea was defined as
an unusually frequent passage of loose stools that required
intervention. The mean dose of prednisolone (mg/kg per
day) over the 12-month study period was calculated. Blood
pressure was also measured, and the patient was checked
for gingival hyperplasia and hypertrichosis. An automatic
device was used to measure blood pressure, which was then
compared to that of healthy children of the same gender,
age and height [24]. Hypertension was defined as a systolic
and/or diastolic blood pressure >1.64 SDS (95th percentile)
or when antihypertensive medication was prescribed (ex-
cluding indications such as proteinuria or headache).
In addition, blood count, serum creatinine, serum
albumen, CsA or MMF trough levels and urine protein/
creatinine were determined. The GFR was calculated using an
adapted Schwartz formula [25, 26]. Serum lipids [cholesterol,
triglycerides, low-density lipoprotein-cholesterol (LDL) and
high-density lipoprotein cholesterol (HDL)] were measured
at study entry and after 1 year.
Pharmacokinetic study of mycophenolic acid
Mycophenolic acid (MPA) area under the curve (AUC) was
determined after 3–6 months of treatment, while patients
were in remission, by the limited sampling method
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according to Schütz [27]. Blood samples were taken
predose and 75 and 360 min after the morning dose. The
AUC was calculated using the formula AUC ¼ 5:2þ 7:1
C0min þ 1 C75min þ 5:4 C360min. To measure the levels
of MPA, we used an immunoassay for ten patients (EMIT–
MPA Assay; Behring Diagnostics, San Jose, CA) and a
high-pressure liquid chromatography system with a UV
detector (HPLC-UV; Merck-Hitachi, Stuttgart, Germany)
for two patients.
Statistics
Patients were stratified for both recent use of CsA and
treatment centre and subsequently randomized, based on a
computer-generated randomization list, using opaque sealed
envelopes prepared by the trial statistician. Study-patients
and investigators were not blinded to treatment group.
Patients who did not complete the 12-month study period
were included in the analysis according to the intention-to-
treat-principle.
The primary end point in this study was GFR. Secondary
end points were relapse-free survival time, occurrence of
diarrhea, blood pressure and blood count parameters.
Assuming a standard deviation for GFR of 20 ml/min per
1.73 m2, we calculated that 20 patients in each group was
sufficient to detect a difference in GFR of 18 ml/min per
1.73 m2 between both groups (p<0.05, power=80%). We
had aimed at 20 patients in each group, but failed to enrol
these, among other reasons due to the growing preference
of MMF treatment in this group of patients.
Differences between the groups at baseline were tested
with the Mann–Whitney U test for continuous data and the
chi-square test for categorical data. Kaplan–Meier curves
were used to compare relapse-free survival time between
the two groups. Relapse rate, prednisolone dose and MPA
trough levels were analysed by the Mann-Whitney U test.
The longitudinal measurements of GFR, blood pressure and
blood count parameters were analyzed using repeated
measurements analysis of variance (ANOVA) with baseline
values as covariates. The GFR was logarithmically trans-
formed in this analysis to approximate normal distributions.
Serum lipids were analysed by ANOVA. A p value < 0.05
was considered to be significant. All computations were
carried out in SPSS ver. 11.5 (SPSS, Chicago, IL).
Results
Of the 31 randomized patients with frequently relapsing
nephrotic syndrome who were originally selected for the
study, seven were excluded (Fig. 1). The remaining 24
children were evaluated during the study, and their patient
characteristics at baseline are summarized in Table 1. Renal
biopsy was performed 20 months (median, range 0–110
months) prior to the onset of the study. Cyclophosphamide
was given in 23 of the 24 patients at a dosage of 2–3 mg/kg
per day for 8 weeks. The study medication was discon-
tinued during the study-period in two patients receiving
MMF (see Efficacy).
Glomerular filtration rate
Mean estimated GFR in the MMF group increased by
6 ml/min per 1.73 m2 in 1 year; during the same period, the
estimated GFR in the CsA group declined by 14 ml/min per
1.73 m2 (Table 2). The use of CsA medication prior to
randomization did not cause a significant difference in GFR
between both groups (mean change in GFR with or without
prior CsA medication in the MMF group was 5 ml versus
7 ml/min per 1.73 m2; in the CsA group, this was −10 vs.
−16 ml/min per 1.73 m2, respectively). Follow-up values
for GFR were on average 13% lower (95% confidence
interval: 1–23%, p=0.03) in patients treated with CsA.
After 3, 6 and 12 months of drug therapy, the mean GFR of
the CsA group was significantly lower than the baseline
value (p=0.048, 0.041, 0.013, respectively); this is in
contrast to the MMF group, where no significant changes
from baseline were found (Fig. 2). One patient with CsA
had slightly impaired renal function (GFR 77 ml/min per
1.73 m2) at the end of the study period, while none of the
patients in the MMF group showed any sign of renal
impairment.
Fig. 1 Flow chart of the study comparing mycophenolate mofetil
(MMF) and cyclosporine (CsA) for remission maintenance in
nephrotic syndrome. Asterisk indicates frequent relapses. There was
one request for withdrawal from the study
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Efficacy
The relapse-free survival curve is shown in Fig. 3. An
overview of the number of relapses during the study-period
is given in Table 3. Although the relapse rate in the MMF
group (0.83/year±1.27 SD) appears to be higher than that
in the CsA group (0.08/year±0.29 SD), the difference did
not reach significance (p=0.08). One patient with MMF
experienced treatment failure, with three relapses within
6 months, which was reason to switch to CsA. While on
CsA for the remaining 6 months of the study, this patient
had one more relapse. Of the two patients in the MMF
group with two relapses each, one patient admitted to be
non-compliant and switched after 6 months to CsA therapy
at his own request because of a loss of appetite and
recurrence of eczema; the other patient had two dose
reductions (see Side effects). Two of five patients with
relapses in the MMF group had previous treatment with
CsA, versus three of the seven without relapses. The mean
prednisolone dose during the 12-month study period was
Table 1 Patient characteristics
and previous treatment for
nephrotic syndrome
Data are given as number of
patients or as the median, with
the range in parenthesis
MMF Mycophenolate mofetil;
CsA cyclosporine A
Patient characteristics MMF CsA p
Number of patients 12 12
Male 10 11 1.00
Age (years) 10.9 (4.0–15.2) 9.2 (3.7–17.5) 0.81
Duration of nephrotic syndrome (years) 5.3 (1.1–11.4) 5.2 (1.1–12.3) 0.99
Steroid dependency 8 8 1.00
Previous treatment
Cyclophosphamide 12 11 1.00
Months before study entry 22 (5–103) 47 (5–153) 0.65
Levamisole 0 1
CsA 5 6 1.00
Duration of CsA medication (years) 2.2 (1.4–3.2) 4.0 (1–10) 0.51
Table 2 Results from the clinical and laboratory tests throughout the study
Clinical and laboratory
parameters
Therapeutic drug
programme
0 months 3 months 6 months 9 months 12 months pa
GFR (ml/min per 1.73 m2) MMF 125 (34) 123 (33) 126 (26) 125 (31) 131 (40) 0.03
CsA 123 (22) 112 (26) 107 (16) 114 (18) 109 (16)
Systolic blood pressure (SDS) MMF 1.04 (0.89) 0.87 (0.84) 0.61 (0.83) 0.89 (0.68) 0.62 (0.71) 0.17
CsA 1.35 (0.93) 1.19 (0.56) 1.13 (0.78) 1.17 (1.05) 0.88 (1.16)
Diastolic blood pressure (SDS) MMF 0.36 (0.77) 0.44 (0.80) 0.22 (0.63) 0.27 (0.71) 0.05 (0.68) 0.57
CsA 0.21 (0.83) −0.05 (0.77) 0.00 (0.72) 0.12 (0.89) 0.30 (0.91)
Haemoglobin (g/dl) MMF 13.5 (1.1) 13.2 (1.0) 13.0 (1.4) 13.0 (1.0) 13.5 (1.1) 0.005
CsA 13.0 (1.3) 12.2 (0.6) 12.0 (0.3) 11.9 (0.8) 12.0 (1.0)
Leucocytes (×1000 cells/mm3) MMF 7.3 (2.6) 6.7 (1.9) 7.4 (3.9) 6.5 (2.1) 6.1 (1.7) 0.43
CsA 8.1 (2.8) 7.0 (1.7) 7.7 (2.2) 7.7 (2.6) 8.1 (3.0)
Lymphocytes (×1000 cells/mm3) MMF 2.5 (1.3) 2.5 (0.9) 2.0 (0.9) 2.0 (0.9) 2.0 (0.7) 0.99
CsA 2.8 (1.2) 2.3 (0.6) 2.3 (0.8) 2.0 (0.8) 2.3 (0.5)
Cholesterol (mg/dl) MMF 196 (81) 181 (89) 0.59
CsA 181 (42) 177 (31)
Triglycerides (mg/dl) MMF 114 (50) 84 (30) 0.59
CsA 114 (50) 85 (40)
LDL-cholesterol (mg/dl) MMF 104 (23) 85 (19) 0.10
CsA 112 (46) 116 (35)
HDL-cholesterol (mg/dl) MMF 58 (15) 54 (8) 0.60
CsA 54 (12) 58 (12)
All values are means, with the standard deviation given in parenthesis
GFR, Glomerular filtration rate; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol
a The p value compares the overall change from baseline between the two groups
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not significantly different between the two groups (Table 3).
Steroids were only given for the treatment of relapses, with
the exception of one patient in the CsA group, who
received low dose prednisolone (5 mg) on alternate days
as maintenance therapy.
Side effects
The side effects of MMF drug therapy were generally mild,
and most patients tolerated MMF well. The MMF dose of
one patient was reduced by 25% during a bout of
pneumonia, and a few months later an additional 25%
reduction was implemented because of unexplained fatigue;
dose modification was not necessary in the other patients.
None of the patients experienced diarrhea; however, one
patient had a temporary slight increase in defecation
frequency (one to three defecations per day), without other
gastro-intestinal symptoms or weight loss.
Blood pressure
Mean blood pressure did not change significantly in both
groups during the study period (Table 2). After 12 months,
one patient on MMF—compared to four patients on CsA—
had hypertension, whereas at baseline four and three
patients, respectively, were hypertensive (p=0.32). One
patient in the MMF group was treated for hypertension with
angiotensin-converting enzyme (ACE) inhibition at study
entry; this was withdrawn during the study period.
Antihypertensive drugs were not prescribed for any other
indications (e.g. proteinuria or headache).
Laboratory parameters
The laboratory results on the blood count and serum lipids
are given in Table 2. At 12 months, the haemoglobin (Hb)
level was significantly lower in the CsA group than in the
MMF group (p=0.005). None of the patients developed
anemia (Hb <10.4 mmol/l in more than one measurement)
or leucopenia (leucocytes <4.0×1000 cells/mm3 in more
than one measurement). Two patients, one in each group,
developed transient mild lymphopenia (lymphocytes 1.00–
1.50×1000 cells/mm3). Two other patients in the MMF
group, both with pre-existing lymphopenia (1.1 and 0.98×
1000 cells/mm3, respectively), continued to have low
Fig. 2 Change in the glomerular filtration rate (GFR) from baseline
for patients receiving mycophenolate mofetil (MMF, n = 12) and
cyclosporine A (CsA, n = 12) medication. The change in the GFR is
expressed as ratio compared to baseline. Data are given as ANOVA
estimates with standard errors. *p<0.05 compared to baseline
Fig. 3 Relapse-free survival curve for patients with mycophenolate
mofetil (MMF, n = 12) and cyclosporine A (CsA, n = 12) medication.
The p value is from the logrank test
Table 3 Efficacy of MMF compared to CsA
Parameter MMF CsA p
Patient (n) 12 12
CsA (mg/kg per day) - 5.1 (1.1)
MMF (mg/m2 per day) 1173 (114) -
Prednisolone (n)a 9 5 0.21
Mean prednisolone dose
(mg/kg/day)
0.13 (0.16) 0.08 (0.12) 0.21
Number of relapses (n)
Zero 7 11
One 2 1
Two 2 0
Four 1 0
Relapse rate (n/patient
per year)
0.83 0.08 0.08
Data are given as mean, with the standard deviation given in
parenthesis
a Including patients using prednisolone started just before study-entry
as relapse treatment
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lymphocyte counts (minimum 0.95×1000 cells/mm3) without
infections.
Hypertrichosis and gingival hyperplasia
After 12 months, hypertrichosis occurred in three of eight
patients on CsA drug therapy; in contrast none of the
patients on MMF medication developed hypertrichosis.
Gingival hyperplasia was observed in six of ten patients in
the CsA group versus none in the MMF group.
Pharmacokinetic study
Pharmacokinetic profiles of MPAwere determined in seven
patients (Fig. 4). During AUC determination, all patients
were in remission and using 1098–1315 mg/m2 per day
MMF. One patient received co-medication with benazepril
and cetirizine, and another patient received prednisolone,
calcium and vitamin D; all other patients received MMF
monotherapy. The patient with the lowest AUC had three
relapses within 6 months while using MMF 1315 mg/m2
per day and showed no evidence of non-compliance
For ten patients on MPA drug therapy, four with relapses
and six without, one or more MPA trough levels were
available. Mean MPA trough level of patients with relapses
was 3.4 (SD 2.4) mg/l compared to 3.6 (SD 1.0) mg/l of
patients without relapses (p=0.48).
Discussion
The current standard treatment of frequently relapsing
nephrotic syndrome in children with long-term prednisolone
is successful but eventually leads to unwanted side effects,
such as osteopenia, growth failure and cataract. A switch of
medication is then necessary to prevent further relapses of
nephrotic syndrome. The long-term treatment of children
with CsA is effective but also has unfavourable side effects,
of which hypertension and nephrotoxicity are the most
important [6–11]. An alternative is welcome, and recent
studies suggest a positive effect of MMF in children with
nephrotic syndrome of various etiologies [12–21]. Here we
report the first randomized controlled trial comparing the
side effects and efficacy of MMF and CsA in children with
frequently relapsing nephrotic syndrome.
The side-effect profile of MMF in our patients was more
favourable than that of CsA. The mean estimated GFR in
the MMF group increased with 6 ml/min per 1.73 m2
during 1 year of treatment compared to a decline of 14 ml/min
per 1.73 m2 in the CsA group. This finding is in line with
previous studies in which no nephrotoxicity of MMF was
reported [28]. The reduction in the GFR in the CsA-treated
patients may be related to the vasoconstrictive effects of CsA
[7, 8]. Although this haemodynamic effect can be reversible
following the cessation of therapy, long-term treatment is
often needed for remission maintenance in these children. In
addition, it is well known that even after only 1 year of treat-
ment with CsA, tubulointerstitial lesions can be found [29].
As expected, hypertrichosis and gingival hypertrophy were
only seen in patients treated with CsA. Although diarrhea
occurs in up to 43% of transplant recipients treated with
MMF, we found only mild gastrointestinal symptoms, which
is in agreement with recent studies on MMF in nephrotic
children [14, 19]. Surprisingly, our analysis of haemato-
logical parameters revealed that patients in the MMF group
had a significantly higher haemoglobin level at 12 months
than those in the CsA group. This finding is in contrast with
studies reporting a negative effect of MMF on erythropoiesis
in renal transplant recipients [30, 31]. However, none of our
patients developed anemia, nor did any of the patients suffer
from significant leucopenia or lymphopenia.
Our data suggest that CsA is more effective in preventing
relapses thanMMF, but the number of patients in our study is
too small to draw definite conclusions on this endpoint.
Despite the lack of previous randomized controlled trials
proving the efficacy of MMF in nephrotic syndrome,
pediatric nephrologists already feel that MMF is effective
in these children. This made recruitment for our study
difficult and explains the small number of children enrolled.
However, taking into account that all patients had a
history of frequently relapsing nephrotic syndrome, the
current relapse rate of <1 /patient per year even in the MMF
group is a positive finding. One patient on MMF
medication experienced treatment failure, with three relapses
within 6 months, and needed alternative treatment. This
patient had the lowest AUC of MPA. We hypothesize that
Fig. 4 Mycophenolic acid levels with area under the curve.
Mycophenolic acid levels were measured using an immunoassay
(filled symbols) or by high-performance liquid chromatography–
ultraviolet test (open symbols). Unbroken line no relapses, broken
line three relapses in 6 months
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dose adjustment in this patient might have improved the
efficacy of the MMF drug therapy. An AUC was not
available for the two patients with two relapses. One of
these appeared to be non-compliant; in the second patient,
the MMF was tapered to 50% of the original dose. As such,
these patients may have had suboptimal MPA levels. Based
on these anecdotal observations as well as on reports by
others, we suggest that the issue of dose dependency should
be further addressed in any prospective MMF trial in the
future [13, 20, 23].
We used two methods for therapeutic drug monitoring:
EMIT and HPLC. Westley et al. showed a good correlation
between both methods (r2=0.851), with a small overesti-
mation of MPA plasma concentration with the EMIT in the
therapeutic range EMIT ¼ 0:973HPLCþ 0:55ð Þ [32]. The
pharmacokinetic profiles of MPA depict a lower level in six
of seven patients after 6 h compared to predose level; this is
due to the enterohepatic circulation of MPA glucuronide,
which undergoes deglucuronidation and reabsorption
as MPA [33, 34]. In renal transplant children, a secondary
increase in MPA levels was observed, occurring 6–12 h
after ingestion, which was compatible with enterohepatic
recirculation [34, 35].
The preponderance of males in our study differs from the
male:female ratio of 1.5 in children with first episode
nephrotic syndrome, but it is in concert with a higher
relapse frequency found in boys [1, 36, 37].
In conclusion, this study suggests a beneficial effect of
MMF in children with frequently relapsing minimal change
nephrotic syndrome. However, although MMF may not be
as efficacious as CsA, the side-effect profile of MMF is
much more benign. We postulate that there is a role for
MMF in the treatment of frequently relapsing nephrotic
syndrome in children; however, larger randomized controlled
trials with therapeutic drug monitoring and individual dose
adjustment are warranted.
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